Core Viewpoint - The company has received acceptance for its H-share full circulation filing by the China Securities Regulatory Commission, which is expected to enhance liquidity, governance, and market competitiveness, driving business growth and shareholder value [1] Group 1: Company Developments - The company's stock price increased by 2.17% to HKD 49.40 on June 10, following the announcement of the H-share full circulation application [1] - The company has six products approved in China and four internationally, reaching over 50 countries and benefiting more than 800,000 patients globally [2] - The company has been included in the MSCI Global Small Cap Index, which is likely to attract more international capital [2] Group 2: Research and Clinical Trials - The company showcased its research results at the American Society of Clinical Oncology (ASCO) annual meeting, including the innovative anti-HER2 monoclonal antibody HLX22 and the anti-PD-1 monoclonal antibody H药 汉斯状® [1] - The company presented Phase I clinical trial data for HLX43 (PD-L1 ADC) for treating advanced/metastatic solid tumor patients, addressing issues of non-response or resistance to PD-1/L1 immunotherapy [1]
复宏汉霖(02696)H股全流通备案申请获证监会受理 流动性提升叠加市场竞争力增强或助公司高速发展